Flag of the European Union EU Clinical Trials Register Help

Clinical trials for decitabine OR 2

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    38,657 result(s) found for: decitabine OR 2. Displaying page 211 of 1,933.
    «« First « Previous 207  208  209  210  211  212  213  214  215  Next» Last»»
    EudraCT Number: 2014-004725-40 Sponsor Protocol Number: ECOBT Start Date*: 2015-11-04
    Sponsor Name:Consorci Mar Parc de Salut de Barcelona (Parc de Salut MAR)
    Full Title: Interfascial effectiveness of ultrasound-guided blocking in transurethral resection of bladder tumor
    Medical condition: Bladder cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001563-36 Sponsor Protocol Number: CRAD001MIL04T Start Date*: 2016-05-12
    Sponsor Name:Novartis Pharmaceuticals
    Full Title: A Phase II Study of RAD001 in the Treatment of Patients With Plexiform Neurofibromas (PN) Associated With Neurofibromatosis Type 1 (NF1)
    Medical condition: Plexiform Neurofibroma Associated With Neurofibromatosis Type 1
    Disease:
    Population Age: Children, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-000112-42 Sponsor Protocol Number: V501-028 Start Date*: 2017-01-11
    Sponsor Name:Banyu Pharmaceutical Co., Ltd. a subsidiary of Merck & Co., Inc, Kenilworth, New Jersey
    Full Title: A Phase II Double-Blind Comparative Study of V501 in Females Aged 9 to 17 Years
    Medical condition: vaccination against HPV infection/related disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004865 10071147 Human papilloma virus immunization LLT
    Population Age: Children, Adolescents, Under 18 Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-003798-16 Sponsor Protocol Number: IgPro20_1001 Start Date*: 2018-06-20
    Sponsor Name:CSL Behring LLC
    Full Title: Comparison of 2 Infusion Devices with Respect to Pharmacokinetics, Safety, and Tolerability of Hizentra®: Investigational Wearable Infusor and the Crono S-PID-50 Infusion Pump
    Medical condition: Pharmacokinetics in subjects with PID
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-000628-24 Sponsor Protocol Number: MO16/053 Start Date*: 2018-01-12
    Sponsor Name:University of Leeds
    Full Title: A randomised placebo-controlled phase III trial of the effect of the omega-3 fatty acid eicosapentaenoic acid (EPA) on colorectal cancer recurrence and survival after surgery for resectable liver m...
    Medical condition: Colorectal cancer liver metastases
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007095 Cancer of liver, secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-000843-29 Sponsor Protocol Number: MS316 Start Date*: 2019-05-31
    Sponsor Name:Ipsen Pharma
    Full Title: Recombinant Human Growth Hormone (rhGH) and Recombinant Human Insulin-like Growth Factor-1 (rhIGF-1) Combination Therapy in Children with Short Stature Associated with IGF-1 Deficiency: A Six-year,...
    Medical condition: Idiopatic Short Stature in prepubertal children associated with low IGF-1 and normal stimulated GH response
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-003036-23 Sponsor Protocol Number: 19SM5101 Start Date*: 2019-12-02
    Sponsor Name:Imperial College London
    Full Title: Mechanisms of adverse effects of long-acting beta-agonists in asthma
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003638 Atopic asthma LLT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003565 Asthmatic LLT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10015575 Exacerbation of asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2004-001648-64 Sponsor Protocol Number: No EP-24332T-A014 Start Date*: 2004-09-16
    Sponsor Name:ardana LTD
    Full Title: A Phase II multicentre, open-label study investigating the pharmacokinetics, pharmacodynamics, efficacy and safety of a loading dose regimen of a new GnRH antagonist, Teverelix 90 mg, long-acting f...
    Medical condition: advanced prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004924-11 Sponsor Protocol Number: SHX0712 Start Date*: 2005-05-20
    Sponsor Name:ALK-Abelló A/S
    Full Title: A multicentre, randomised, double-blind, placebo-controlled parallel group clinical trial to investigate the efficacy and safety of specific sublingual immunotherapy with SLIT One birch in patients...
    Medical condition: Desensibilisierung gegenüber Allergenen
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001638-34 Sponsor Protocol Number: navaboost Start Date*: 2006-09-28
    Sponsor Name:Health Protection Agency
    Full Title: A phase IV, single group study to evaluate the magnitude of antibody response, its persistence and avidity maturation following meningococcal serogroup C conjugate booster vaccination in older chil...
    Medical condition: Meningococcal Group C Disease
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002849-40 Sponsor Protocol Number: DermHivImm Start Date*: 2006-03-29
    Sponsor Name:Swedish Institute for Infectious Disease Control
    Full Title: Active immunotherapy against HIV during highly active anti-retroviral therapy followed by repeated treatment interruptions, VAC 09.
    Medical condition: Treatment of HIV infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002192-32 Sponsor Protocol Number: UKSH-A105 Start Date*: 2006-07-28
    Sponsor Name:Univeristy Hospital Schleswig-Holstein
    Full Title: Phase II Randomized, Parallel-Group Trial on PTK-ZK with or without DTIC in Patients with non-resectable Metastatic Malignant Melanoma
    Medical condition: non-resectable metastatic malignant melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-006004-11 Sponsor Protocol Number: Keimzelltumor 2007 Start Date*: 2008-01-24
    Sponsor Name:Martin-Luther-Universität Halle-Wittenberg, vertreten durch den Kanzler
    Full Title: Phase II – Studie P-ICE Hochdosischemotherapie mit Paclitaxel, Ifosfamid,Carboplatin und Etoposid mit autologem Stammzellsupport bei männlichen Patienten mit refraktären oder rezidivierten Keimzell...
    Medical condition: patients with malignant germ cell tumor
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020684-20 Sponsor Protocol Number: CLAF237A23135 Start Date*: 2010-09-29
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 24-week, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of vildagliptin 50mg bid as an add-on therapy to insulin, with or witho...
    Medical condition: Type II Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10012594 Diabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed) GB (Completed) BE (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2009-014694-40 Sponsor Protocol Number: SSAT033 Start Date*: 2009-11-11
    Sponsor Name:
    Full Title: A pilot evaluation of the pharmacokinetics, efficacy and safety of switching from efavirenz to maraviroc administered at 600mg then 300mg twice-daily in patients suppressed on an efavirenz-containi...
    Medical condition: HIV
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023103-94 Sponsor Protocol Number: 002:CD40L Start Date*: 2011-07-04
    Sponsor Name:Uppsala University
    Full Title: PHASE I/IIa AdCD40L IMMUNOGENE THERAPY FOR MALIGNANT MELANOMA PATIENTS WITH DISSEMINATED DISEASE
    Medical condition: malignant melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023335-41 Sponsor Protocol Number: 16011 Start Date*: 2011-11-23
    Sponsor Name:Abbott
    Full Title: A Phase 1b/2 Study of TRU-016 in Combination with Rituximab and Bendamustine in Subjects with Relapsed Indolent Lymphoma
    Medical condition: Relapsed Indolent Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000956-32 Sponsor Protocol Number: 20022012 Start Date*: 2012-06-28
    Sponsor Name:St. Antonius Ziekenhuis
    Full Title: Pharmacokinetics of intravenous acetaminophen and its metabolites in morbidly obese patients
    Medical condition: Morbid obesity
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003530-13 Sponsor Protocol Number: 18072011 Start Date*: 2011-12-20
    Sponsor Name:Brighton & Sussex University Hospitals NHS Trust
    Full Title: Randomised phase II window study of short-term preoperative treatment with the PI3K inhibitor GDC-0941 plus Anastrozole versus Anastrozole alone in patients with ER-positive primary breast cancer
    Medical condition: Primary breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006206 Breast carcinoma NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-005010-36 Sponsor Protocol Number: CR-TFB-2013/502 Start Date*: 2014-01-08
    Sponsor Name:Thomas Fichtner Bendtsen
    Full Title: The effect of protracted saphenous nerve and obturator nerve blockade versus saphenous nerve blockade versus local infiltration analgesia in opioid consumption, pain, blockade duration of action an...
    Medical condition: The medical condition to be examined in this study is the first postoperative period after total knee replacement with a view to pain management.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004865 10038286 Regional nerve block LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 207  208  209  210  211  212  213  214  215  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Feb 12 05:30:03 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA